Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP, INTERIM CFO

CHIEF MEDICAL OFFICER

GC & Corporate Secretary

SVP, Interim CFO

Chief Medical Officer

Chief Financial Officer

Chief Technical Officer

Chief Commercial Officer

CEO and President

Chief Operating Officer

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ÃƒÅ¸-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-13	Premium	sold	Premium	Premium	Premium	SVP, INTERIM CFO
2024-02-13	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-10	Premium	acquired	Premium	Premium	Premium	SVP, INTERIM CFO
2024-02-10	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-01-02	Premium	sold	Premium	Premium	Premium	GC & Corporate Secretary
2024-01-02	Premium	sold	Premium	Premium	Premium	SVP, Interim CFO
2024-01-02	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-12-31	Premium	acquired	Premium	Premium	Premium	SVP, Interim CFO
2023-12-31	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-12-31	Premium	acquired	Premium	Premium	Premium	GC & Corporate Secretary
2023-07-28	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-07-28	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-06-28	Premium	bought	Premium	Premium	Premium	-
2023-06-27	Premium	bought	Premium	Premium	Premium	-
2023-06-16	Premium	sold	Premium	Premium	Premium	Chief Technical Officer
2023-06-15	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2023-04-18	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-04-18	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-12-01	Premium	sold	Premium	Premium	Premium	-
2022-11-22	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2022-11-22	Premium	sold	Premium	Premium	Premium	Chief Technical Officer
2022-09-19	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2022-09-15	Premium	acquired	Premium	Premium	Premium	Chief Commercial Officer
2022-05-04	Premium	bought	Premium	Premium	Premium	-
2022-05-03	Premium	bought	Premium	Premium	Premium	-

PASG - Passage Bio Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for PASG